|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A valine-108-methionine polymorphism in exon 4 of the catechol-O-methyltransferase (COMT) gene causes a 3- to 4-fold reduction in enzyme activity and has been associated with an increased risk of breast cancer.
|
11142424 |
2000 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
To date, three studies in Caucasians and one study in Chinese have been conducted to determine the association with breast cancer risk of a functional polymorphism (G-to-A, Val158Met) of this enzyme, but the results were inconsistent.
|
11706521 |
2001 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Several studies have indicated that the val108met COMT polymorphism, which results in a 3-4-fold decrease in activity, is associated with increased breast cancer risk.
|
11577006 |
2001 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer.
|
11434504 |
2001 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Val158Met Polymorphism in catechol-O-methyltransferase gene associated with risk factors for breast cancer.
|
14504192 |
2003 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
When MnSOD Ala was combined with either cytochrome P450 1B1 CYP1B1*1 and catechol O-methyltransferase COMT-L (V158M) genotypes, the risk for developing breast cancer was significantly increased in patients with a body mass index (BMI) greater than 24 kg m(-2) (OR: 1.42 (95%CI=1.04-1.93)).
|
15386537 |
2005 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We investigated the associations between breast cancer and sequence variants in several genes in the estradiol/estrone metabolism pathway (CYP1A1*2A, CYP1A2*1F, CYP1B1 Leu432Val, CYP3A4*1B, COMT Val158Met, SULT1A1Arg213His) as well as the Arg554Lys variant in AHR (a transcription factor for CYP1A1, CYP1A2, and CYP1B1) in a case-control study of 1,339 breast cancer cases and 1,370 controls nested in the Multiethnic Cohort Study.
|
16103451 |
2005 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A functional Val158Met polymorphism in the COMT gene has been known as a susceptible marker for breast cancer.
|
17047485 |
2006 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we evaluated the frequency of different polymorphisms related with estrogen metabolism [COMT Val158Met, CYP17 (5'UTR, T27C); HSD17beta1 Gly313Ser and MnSOD Val16Ala] in a breast cancer resistant population, the Xavante Indians, and the frequencies were compared with the ones reported in other populations where breast cancer case-control studies dealing with these polymorphisms have been carried out.
|
16969494 |
2006 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Haplotypes in another LD block, which included COMT Val(158)Met, were not associated with breast cancer risk (global P = 0.76).
|
17018638 |
2006 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Results from this study suggest that rs4680 in the COMT gene and rs4646903 in the CYP1A1 gene may be genetic markers for breast cancer prognosis in Chinese women.
|
17429315 |
2007 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study we evaluated the association between the interleukin-1B C-31T, catechol-O-methyltransferase Val158Met, and thymidylate synthase (TS) 1494del6 polymorphisms and breast cancer.
|
17385677 |
2007 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
When stratified by menopausal status, COMT Val158Met L/L (OR: 11.94; 95% CI: 1.48-96.03, P=0.02) and ERalpha PvuII P/p genotypes (OR: 2.67; 95% CI: 1.01-7.05, P=0.048) were associated with a significantly elevated risk of breast cancer in premenopausal women, and there was a association between ERalpha XbaI x/x genotype and the nonsignificantly increased risk of breast cancer in premenopausal women (OR: 6.88; 95% CI: 0.80-59.15, P=0.079).
|
17562079 |
2007 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
COMT rs4680 genotypes did not have a modifying effect on the association of green tea intake with breast cancer risk.
|
19074205 |
2009 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although CYP1B1 and COMT genotypes did not exhibit statistically significant association with breast cancer risks when analyzed individually, COMT wild type (Val(158)Val) in combination with CYP1B1 heterozygous variant (Leu(432)Val) [OR: 0.21; 95% CI (0.05-0.82), p value; 0.021] and COMT heterozygous variant (Val(158)Met) in combination with CYP1B1 wild type (Leu(432)Leu) [OR: 0.29; 95% CI (0.08-0.96), p value; 0.042] showed significant protective association with premenopausal breast cancer risk.
|
20037207 |
2009 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, COMT Val158Met polymorphism may be a low-penetrant risk factor for breast cancer development in European population.
|
20130981 |
2010 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conducted a large population-based case control study in Massachusetts, New Hampshire, and Wisconsin to examine six strategically selected COMT haplotype-tagging (ht) single nucleotide polymorphism (SNPs), including the val158met polymorphism (rs4680), in relation to breast cancer risk.
|
20150638 |
2010 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic polymorphism Val158Met of catechol-O-methyltransferase (COMT) may contribute to estrogen-induced carcinogenesis of breast cancer.
|
20591221 |
2010 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, when this relation was assessed within strata based on estrogen-related factors, a few SNPs (HSD17B1 (rs2010750, rs598126 and rs676387), COMT (rs4680), UGT1A1 (rs8175347) and ESR1 (rs9340799)) seemed to be related to MD in the same direction of their associations with breast cancer risk.
|
22199302 |
2011 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
No association between COMT 1947 G>A (rs4680) or CYP1A1 4889 A>G (rs1048943) and breast cancer was found.
|
20878621 |
2011 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A case-control study was conducted to assess the associations between soy isoflavone intake and the CYP1A1 Ile462Val, CYP1B1 Val432Leu, and COMT Val158Met polymorphisms and breast cancer, as well as their combined effects on breast cancer.
|
21438753 |
2011 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our meta-analysis results suggest that the COMT Val158Met polymorphism may not contribute to breast cancer susceptibility.
|
23039364 |
2012 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, this meta-analysis indicates that COMT Val158Met polymorphism may be associated with decreased breast cancer</span> risk in Caucasian population.
|
22297695 |
2012 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Influence of catechol-o-methyltransferase genotype (Val158Met) on endocrine, sympathetic nervous and mucosal immune systems in breast cancer survivors.
|
21974969 |
2012 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Catechol-O-methyltransferase genotype (Val158met) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors.
|
21898113 |
2012 |